1 e therapy to SOC treatment with atropine and pralidoxime.

2 tes of acetylcholinesterase by two oximes, 2-pralidoxime (2-PAM) and 1-(2'-hydroxyiminomethyl-1'-pyri

3 eactivating AChE, the action of drugs like 2-pralidoxime (2-PAM) is primarily limited to the peripher

4 vo efficacy compared to the current antidote pralidoxime (2-PAM).

5     The use of adult formulated atropine and pralidoxime autoinjectors will deliver doses above curre

6 ld be given a full dose of both atropine and pralidoxime from the Mark 1 kit when more accurate weigh

7 ombination of Cu-DEHN-mediated catalysis and pralidoxime iodide-triggered enzymatic reactivation was

8 ulsion, lidocaine, methylene blue, naloxone, pralidoxime, sodium bicarbonate, sodium nitrite, sodium

9 that NV354, in combination with atropine and pralidoxime therapy, significantly improved cerebral mit

10 y fenthion or dimethoate responded poorly to pralidoxime treatment compared with chlorpyrifos-inhibit